Number 5: Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for ...
The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands ...
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...
Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...
Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and ...
The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...
A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal ...
Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...
The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...
Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...
On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...
In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback